Appeal No. 1997-0875
Application No. 07/998,128
OPINION
Schwarz discloses a tissue adhesive comprising specified amounts of factor XIII,
fibrinogen, cold-insoluble globulin (i.e., fibronectin), albumin and plasminogen-activator
inhibitor or plasmin inhibitor (c.1, l. 57 - c. 2, l. 2), made from human or animal plasma
cryoprecipitate (c. 2, ll. 63-65). The adhesive is applied either in combination with or after
application of a mixture of thrombin and calcium ions to a tissue, e.g., to seal wounds, stop
bleeding and stimulate wound healing (c. 3, ll. 18-22 and 30-33).
Zimmerman discloses a wound healing and sealing composition comprising
"fibrinogen particles and thrombin particles or thrombin-liberating particles ... present
alongside one another on a collagen carrier, without reacting with one another" (c. 2, ll. 59-
62). The fibrinogen and thrombin components only form fibrin when serum-like fluid or
blood reaches them so that fibrin formation takes place at a predetermined time and place
(c. 3, ll. 56-60).
Mann discloses a wound healing composition comprising human platelet cell
proliferation factor (HPPF) in combination with at least one co-factor selected from other
cell growth factors, cell attachment factors and plasminogen activators and inducers
thereof (p. 2, ll. 11-13; p. 4, ll. 34-36). Mann hypothesizes that the composition induces (a)
- 4 -
Page: Previous 1 2 3 4 5 6 7 8 9 10 Next
Last modified: November 3, 2007